Patent ID: 7919577

Claim:
A composition comprising an isolated ACTH analog peptide or pharmaceutically acceptable salt thereof, wherein said ACTH analog peptide consists of the formula: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-Asn-A26-Ala-Glu-A29-A30-Ser-Ala-Glu-Ala-Phe-A36-Leu-Glu-Phe-R wherein: A1 is Ser or D-Ser; A2 is Tyr or D-Tyr; A3 is Ser or D-Ser; A4 is Met, D-Met or Nle; A5 is Glu, D-Glu, Cys or Asp; A6 is His or D-His; A7 is Phe, D-Phe, D-p-iodo-Phe or D-1-napth-Ala; A8 is Arg or D-Arg; A9 is Trp or D-Trp; A10 is Gly, Cys, Lys, Orn, Dab or Dpr; A11 is Lys, D-Lys or Gly; A12 is Pro or D-Pro; A13 is Val or D-Val; A14 is Gly; A15 is Lys, Gly, Val, Leu, Ile, Nle, or an amino acid with an alkyl side chain; A16 is Lys, Gly, Val, Leu, Ile, Nle, or an amino acid with an alkyl side chain; A17 is Arg, Ala, Gly, Val, Leu, Ile, Nle, or an amino acid with an alkyl side chain; A18 is Arg, Ala, Gly, Val, Leu, Ile, Nle, or an amino acid with an alkyl side chain; A19 is Pro, Trp or Ala; A20-A21-A22-A23-A24 is Val-Lys-Val-Tyr-Pro (SEQ ID NO: 18) or Ala-Ala-Ala-Ala-Ala (SEQ ID NO: 19); A26 is Gly or Val; A29 is Asp or Asn; A30 is Glu; A36 is Pro; and R is OH or a pharmaceutically acceptable salt moiety; and wherein, A16-A17-A18 does not include two adjacent amino acid residues selected from the group consisting of: Lys and Arg; and the amino acid sequence at positions 25-39 is optionally deleted said ACTH analog peptide is not Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Arg-Ala-Ala-Trp-Val-Lys-Val-Tyr-Pro-Ac (SEQ ID NO: 20).